From: Antibiotic resistance in Pakistan: a systematic review of past decade
Characteristics | No of studies | References |
---|---|---|
Bacterial Identification method | ||
Morphology/Biochemical testing | 30 (38.961%) | [24, 26, 31, 34, 35, 38, 41,42,43, 47, 49, 50, 53,54,55, 57, 60, 62, 63, 66, 67, 92,93,94,95,96,97,98, 100, 101] |
API | 24 (31.168%) | [10, 13,14,15,16,17,18,19, 21, 22, 28, 32, 33, 36, 37, 51, 52, 56, 70,71,72,73, 90, 99] |
VITEK | 4 (5.195%) | |
MALDI-TOF | 1 (1.299%) | [59] |
PCR | 8 (10.390%) | |
Not mentioned | 10 (12.987%) | |
Phenotypic detection method∆ | ||
DDM* | 63 (81.818%) | [10, 13, 14, 16,17,18,19,20, 22,23,24,25,26,27,28,29,30,31, 33,34,35,36,37,38,39, 41,42,43, 46, 47, 49,50,51,52, 54,55,56,57,58,59,60,61,62, 64, 66,67,68, 70,71,72,73, 90,91,92,93,94,95,96,97,98,99,100, 102] |
Dilution | 15 (19.48%) | [14, 15, 17, 18, 20, 21, 23, 26, 30, 32, 45, 55, 63, 67, 96] |
E Testρ | 7 (9.091%) | |
Vitek2 | 4 (5.195%) | |
Not mentioned | 2 (2.597%) | |
Break point references guidelines∆ | ||
CLSI° | 59 (76.623%) | [6, 13,14,15,16,17,18,19,20,21,22,23,24,25,26, 30,31,32,33,34,35,36, 38,39,40,41,42,43, 45, 47,48,49,50,51,52,53,54,55,56,57,58, 60,61,62,63,64, 66,67,68,69, 71, 90, 91, 93,94,95,96, 99, 101] |
EUCASTγ | 2 (2.597%) | |
Not mentioned | 17 (22.078%) | [9, 10, 27,28,29, 44, 46, 59, 65, 70, 72, 73, 92, 97, 98, 100, 102] |